Merck第3阶段对微型卫星稳定的转移性直肠癌治疗的试验未能改善总体存活率。 Merck's Phase 3 trial for microsatellite-stable metastatic colorectal cancer treatment failed to improve overall survival.
Merck & Co.宣布，其关于favezelimab和pembrolizumab联合治疗微卫星稳定转移性结直肠癌的3期试验并未达到提高总生存期的主要终点。 Merck & Co. announced that its Phase 3 trial of the favezelimab and pembrolizumab combination for treating microsatellite-stable metastatic colorectal cancer did not meet the primary endpoint of improving overall survival compared to standard care. 虽然安全性与之前的研究保持一致,但这一挫折是Keytruda最近试验中其他令人失望的结果的结果. While the safety profile remained consistent with earlier studies, this setback follows other disappointing results for Keytruda in recent trials. 尽管如此,分析师仍然对Merck的股票持乐观看法。 Despite this, analysts maintain a positive outlook on Merck's stock.